Guideline Video

Guideline Resources

Video Transcription

Just published January 6th, 2026, the American Society of Clinical Oncology, also known as ASCO, and Cancer Care Ontario’s newest guideline update on Treatment of Multiple Myeloma.

The purpose of this guideline is to update the evidence-based recommendations on the treatment of multiple myeloma first published jointly by ASCO and Cancer Care Ontario in 2019.

In today’s rapid update video, we’ll just be going over the key changes and recommendations that were added to this 2026 update. For the full summary of revisions or for the full guideline, make sure to check it out on guidelinecentral.com

Let’s get started. 

For the section on Smoldering Multiple Myeloma

  • Daratumumab therapy may be offered to patients with high-risk smoldering myeloma. 

On to the section on Transplant-Eligible Multiple Myeloma

  • Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as initial therapy for transplant eligible patients. They should also be offered at least lenalidomide maintenance, with or without daratumumab, carfilzomib, and/or dexamethasone. 

Then on to Transplant-Ineligible Multiple Myeloma

  • Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as therapy for suitable transplant-ineligible patients. 

And last the section on Relapsed Multiple Myeloma

  • Patients with relapsed or refractory multiple myeloma should be offered triplet therapy or T-cell redirecting therapies according to a set of recommended principles.

And there you have it. Make sure to check out the full guideline from the American Society of Clinical Oncology and Cancer Care Ontario and other related clinical decision support tools at guidelinecentral.com.

Copyright © 2026 Guideline Central, all rights reserved.